Novartis AG (NVS) Stock
NYSENVS has an Alpha Score of 58 out of 100 (moderate), computed on Oct 26, 2026 from 3 of 4 sub-scores. 19 members of Congress disclosed 76 trades in NVS since 2014: 40 purchases and 35 sales, most recently Kevin Hern (sale, Aug 27, 2026). 6 of the hedge funds AlphaScala tracks reported NVS in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Renaissance Technologies's at $123.50M. Its trailing P/E ratio is 28.3 and its net margin 17.5% (key statistics as of Oct 29, 2026).
What is NVS's Alpha Score?
How it works →Alpha Score of 58 reflects moderate overall profile with strong momentum, moderate value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Oct 26, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Novartis AG (NVS)?
Most recent: Kevin Hern (sale, Aug 27, 2026); records start Jun 12, 2014.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Kevin Hern R-OK · House | 2026-08-27 | sale | $15k – $50k |
| Alan Armstrong R-OK · Senate | 2026-03-31 | purchase | $1k – $15k |
| Alan Armstrong R-OK · Senate | 2026-03-30 | purchase | $15k – $50k |
| Lisa McClain R-MI · House | 2025-10-31 | sale | $1k – $15k |
| Lisa McClain R-MI · House | 2025-10-30 | sale | $1k – $15k |
| Lisa McClain R-MI · House | 2025-10-30 | purchase | $1k – $15k |
| Lisa McClain R-MI · House | 2025-09-25 | partial sale | $1k – $15k |
| Lisa McClain R-MI · House | 2025-09-11 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Oct 29, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
See all NVS political trades →Which hedge funds own NVS?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Renaissance Technologies Jim Simons (founder) | 788K | $123.50M | -29% |
| Millennium Management Israel Englander | 758K | $118.80M | NEW |
| Marshall Wace | 330K | $51.73M | +2% |
| Citadel Ken Griffin | 321K | $50.28M | NEW |
| Point72 Steve Cohen | 106K | $16.64M | -63% |
| Maverick Capital Lee Ainslie | 28K | $4.36M | +82% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →What are NVS's key statistics?
Key statistics as of Oct 29, 2026
How does NVS's valuation compare with the Healthcare sector?
| Metric | NVS | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 28.3 | 27.1 | 97 |
| Net margin | 17.50% | 5.48% | 139 |
| Return on equity | 24.55% | 6.84% | 158 |
| Dividend yield (payers) | 3.72% | 1.62% | 50 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 2, 2026). P/E excludes loss-making companies.
NVS price chart
Powered by TradingViewWhat does Novartis AG do?
Novartis AG Sponsored ADR represents the American Depositary Receipts of Novartis AG, a Swiss-based innovative medicines company headquartered in Basel. This ADR enables U.S. investors convenient access to Novartis AG shares, facilitating liquidity and exposure to global pharmaceutical innovation. Novartis AG focuses on researching, developing, producing, distributing, and commercializing advanced treatments across key therapeutic areas, including oncology, immunology, neuroscience, cardiovascular, renal and metabolic diseases, and respiratory conditions. Its portfolio features prominent products such as Entresto and Leqvio in cardiovascular; Cosentyx, Xolair, and Ilaris in immunology; Kesimpta, Zolgensma, and Mayzent in neuroscience; and oncology offerings like Kisqali, Pluvicto, Lutathera, Kymriah, and Scemblix. Additionally, established brands like Lucentis and Sandostatin support ongoing patient care. Operating as a single global segment post its generics spin-off, Novartis AG delivers medicines worldwide, emphasizing research-driven solutions that address serious diseases and enhance healthcare accessibility. Founded in 1996, the company maintains a significant presence in the healthcare sector through its broad therapeutic expertise.